A naturally occurring psychedelic prodrug shaping policy and treatment debates
The US government has implemented new policies to accelerate research and development of psychedelics, including psilocybin, MDMA, and ibogaine. The move involves FDA fast-tracking and funding for state-level studies, aiming to improve treatments for mental health and addiction. This follows recent political and scientific developments.